Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

November 12, 2019

Study Completion Date

November 12, 2019

Conditions

Healthy

Interventions

DRUG

Ciraparantag

Ciraparantag (administered over 10 minutes)

DRUG

Placebo

Saline for injection

DRUG

Rivaroxaban

Rivaroxaban 20 mg given once per day (QD) in the morning

Trial Locations (1)

Frontage Clinical Services Inc., Secaucus

All Listed Sponsors

lead

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

INDUSTRY

NCT03172910 - Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT | Biotech Hunter | Biotech Hunter